Overzicht Proefschriften
Tips in using the search/filter fieldsDisplaying 51-100 of 278 results.
| Titel | Promovendus | Promotor 1 | Promotor 2 | Copromotor 1 | Copromotor 2 | Universiteit | Promotiejaar | Trefwoorden |
|---|---|---|---|---|---|---|---|---|
| Individualized dosing of calcineurin inhibitors in renal transplantation | Press R.R., PhD | Guchelaar H.J., prof. dr. | Fijter J.W. de, prof. dr. | Ploeger B.A., dr. | Universiteit Leiden (UL) | 2011 | Kidney; Transplantation; Calcineurin inhibitors; | |
| Therapeutic drug monitoring: how to improve moxifloxacin exposure in tuberculosis patients | Pranger A. | Kosterink J.G.W., prof. dr. | Werf T.S. van der, prof. dr. | Uges D.R.A., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2018 | drug monitoring moxifloxacin exposure tuberculosis | |
| Future drugs in atherosclerotic cardiovascular disease | Poelgeest E.P van | Burggraaf J., prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2018 | Atherosclerosis Systemic inflammation Hypercholesterolemia PCSK9 inhibitor TLR4 sinaling Acute kidney injury Endothelial dysfunction Human endotoxemia model Ex vivo LPS challenge test Invivo LPS challenge test | ||
| Adherence to antiretroviral combination therapy in children : what a difference half a day makes... | Piana C., PhD | Danhof M., prof. dr. | Della Pasqua O.E., dr. | Universiteit Leiden (UL) | 2013 | Paediatrics; Antiretroviral combination therapy; Compliance; Antiretroviral drugs; Paediatric populations; Drug combinations; Model-based; Covariate analysis; Predictive pharmacokinetic models; Clinical trial simulations; Adherence; Forgiveness of non-adherence; | ||
| Variability in drug response: personalized diabetes care | Petrykiv S.I. | Lambers Heerspink H.J., prof. dr. | Zeeuw D. de, prof. dr. | Laverman G.D., dr. | Rijksuniversiteit Groningen (RUG) | 2017 | ||
| Novel biomarker panels in diabetic kidney disease: predicting disease progression and response to therapy, and monitoring drug effect | Pena M.J., PhD | Zeeuw D. de, prof. dr. | Lambers Heerspink H.J., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2015 | Biomarkers; Diabetes mellitus; Kidney; | ||
| Don't be afraid! Population PK-PD modeling as the basis for individualized dosing in children and critically ill | Peeters M.Y.M., dr. | Danhof M., prof. dr. | Tibboel D., prof. dr. | Knibbe C.A.J., prof. dr. | Universiteit Leiden (UL) | 2007 | Pharmacokinetics; Pharmacodynamics; Children; Sedation; Critically ill; Intensive care; NONMEM; Propofol; Midazolam; | |
| Biomarkers in real-life COPD management | Oshagbemi O.A., PhD | Wouters E.F.M., prof. dr. | Vries F. de, prof. dr. | Franssen F.M.E., dr. | Universiteit Maastricht (UM) | 2019 | ||
| Treatment adherence in hypertension : methodological aspects and new strategies | Onzenoort H.A.W. van, PhD | Leeuw P.W. de, prof. dr. | Neef C., prof. dr. | Kuy P.H.M. van der, dr. | Universiteit Maastricht (UM) | 2012 | Clinical pharmacology; hypertension; compliance | |
| The use of a battery of evoked pain models in early phase drug development | Okkerse P. | Cohen A.F., prof. dr. | Groeneveld G.J., prof. dr. | Universiteit Leiden (UL) | 2018 | Pain Human pain models Analgesics Clinical pharmacology Pharmacodynamics Drug Development | ||
| The pursuit of user-friendly medicines : older people in the hot seat | Notenboom K., PhD | Bouvy M.L., prof. dr. | Leufkens H.G.M., prof. dr. | Universiteit Utrecht (UU) | 2017 | Usability; User-friendly; Older patients; Elderly; Medicines; Medication use; Medication errors; Tablet breaking; Swallowing; Medication packaging; | ||
| Antiplatelet drugs for secondary prevention of cardiovascular diseases : drug utilization, effectiveness, and safety | Noorsyahdy A.Y., MD PhD | Boer A. de, prof. dr. | Klungel O.H., prof. dr. | Deneer V.H.M., dr. | Universiteit Utrecht (UU) | 2017 | Antiplatelet drugs; Secondary prevention; Myocardial infarction; Ischemic stroke; Cardiac arrest; Pharmacogenetics; | |
| Clinical pharmacology of novel anticancer agents: bioanalysis - clinical pharmacokinetics - mass balance studies | Nijenhuis C.M., PhD | Beijnen J.H., prof. dr. | Schellens J.H.M., prof. dr. | Rosing H., dr. | Universiteit Utrecht (UU) | 2016 | ||
| Medication safety in Vietnamese hospital: a focus on medication errors and safety culture | Nguyen T.H., PhD | Taxis K., prof. dr. | Haaijer-Ruskamp F.M., prof. dr. | Brouwers J.R.B.J., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2014 | ||
| Monitoring patients using psychotropic drugs | Nederlof M., PhD | Egberts A.C.G., prof. dr. | Heerdink E.R., dr. | Universiteit Utrecht (UU) | 2018 | Therapeutic drug monitoring; Biomarkers; Benefit-risk assessment; Psychotropic drugs; Psychiatry; Antidepressants; Antipsychotics | ||
| Clinical pharmacology of nevirapine in HIV-infected patients in Tanzania | Muro E.P., PhD | Burger D.M., prof. dr. | Dolmans W.M.V., prof. dr. | Radboud Universiteit (RU) | 2014 | Clinical pharmacology; HIV; Pharmacokinetics; therapy drug monitoring | ||
| Driving-impairing medicines and traffic safety: patients' perspectives | Monteiro S.P., PhD | Gier J.J. de, prof. dr. | Dijk C.E.M.J. van, dr. ir. | Rijksuniversiteit Groningen (RUG) | 2014 | |||
| Aortic pathology and the role of the renin-angiotensin system | Molzer E., PhD | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2011 | Pharmacology; Cardiovascular disease; Renin-angiotensin system; | |||
| Off-target effects of RAAS-inhibition: importance on renal outcomes in patients with diabetes | Miao Y., PhD | Groen A.K., prof. dr. | Zeeuw D. de, prof. dr. | Rijksuniversiteit Groningen (RUG) | 2012 | RAAS-inhibition; Diabetes mellitus; | ||
| Medication optimisation : methodological aspects and new strategies | Mestres Gonzalvo C., PhD | Verhey F.R., prof.dr. | Kuy P.H.M. van der, dr. | Janknegt R., PharmD PhD | Universiteit Maastricht (UM) | 2018 | Elderly; Geriatrics; Hospital pharmacists; Medication use; Model-based; Model validation; Older patients; Optimal pharmacotherapy; Pharmaceutical care; Pharmacotherapy; Pharmacovigilance; | |
| Multi dose drug dispensing for older patients in primary care | Mertens B.J., PhD | Bouvy M.L., prof. dr. | Marum R.J. van, prof. dr. | Kwint H.F., dr. | Universiteit Utrecht (UU) | 2019 | Elderly; Primary care; Multi-dose drug dispensing; | |
| Lithium in older patients : treatment patterns and somatic adverse effects | Melick E.J.M. van, PhD | Egberts A.C.G., prof. dr. | Wilting I., dr. | Universiteit Utrecht (UU) | 2014 | Lithium; Older patients; Pharmacodynamics; Pharmacokinetics; Antidepressants; | ||
| Loss of proteostasis as a substrate for Atrial Fibrilation. | Meijering R.A.M., PhD | Henning R.H., prof. dr. | Brundel B.J.J.M., dr. | Rijksuniversiteit Groningen (RUG) | 2014 | Atrial fibrillation; Proteostasis; | ||
| Pharmacological modulation of ischemia and reperfusion injury | Meijer P., PhD | Rongen G.A., prof. dr. | Smits P., prof. dr. | Radboud Universiteit (RU) | 2012 | Ischemia/Reperfusion injury; rosuvastatin; adenosine; forearm; | ||
| Anti sense and sensibility : renal and skin effects of (antisense) oligonucleotides | Meer, van L., Dr. | Cohen A.F., prof. dr. | Burggraaf J., prof. dr. | Moerland M., dr. | Universiteit Leiden (UL) | 2017 | Oligonucleotide Antisense Type 2 diabetes mellitus Clinical trial Phase2study | |
| The role of differentiation factor 15 in diabetic kidney injury | Mazagová M., PhD | Henning R.H., prof. dr. | Deelman L.E., dr. | Rijksuniversiteit Groningen (RUG) | 2012 | Diabetic kidney disease; Growth differentiation factor 15; | ||
| ColoPulse tablets in inflammatory bowel disease: formulation, potential application and evaluation | Maurer J.M., PhD | Kosterink J.G.W., prof. dr. | Frijlink H.W., prof. dr. | Woerdenbag H.J., dr. | Rijksuniversiteit Groningen (RUG) | 2017 | ColoPulse tablets; Inflammatory bowel disease; | |
| Adverse drug reactions of angiotensin-converting enzyme inhibitors : towards precicion medicine | Mahmoud Pour S.H., PhD | Boer A. de, prof. dr. | Asselbergs F.W., prof. dr. MD FES | Maitland-van der Zee A.H., prof. dr. | Universiteit Utrecht (UU) | 2016 | Adverse drug reaction; Pharmacoepidemiology; Pharmacovigilance; ACE Inhibitors | |
| Strategies for optimization of aminoglycoside and vancomycin therapies | Maarseveen E.M. van, PhD | Neef C., prof. dr. | Touw D.J., prof. dr. | Zanten A.R. van, dr. | 2014 | |||
| Precision anticoagulation with vitamin K antagonists in children | Maagdenberg H., PhD | Boer A. de, prof. dr. | Maitland-van der Zee A.H., prof. dr. | Bierings M.B., dr. | Universiteit Utrecht (UU) | 2018 | Anticoagulation; Thrombosis; Bleedings; Children; Adolescents; Pharmacogenetics; Acenocoumarol; Phenprocoumon; Personalized medicine; Medicines; | |
| The (pro)renin receptor: moving away from prorenin? | Lu X., PhD | Danser A.H.J., prof. dr. | Meima M.E., dr. | Erasmus Universiteit Rotterdam (EUR) | 2014 | Cardiovascular disease; Pharmacology; Prorenin; | ||
| Comorbidities, complications and treatment of childhood obesity | Lentferink Y.E., PhD | Knibbe C.A.J., prof. dr. | Vorst M.M.J. van der, dr. | Universiteit Leiden (UL) | 2019 | Children; Obesity; Asthma; ADHD; Insulin resistance; Metformin; Cardiovascular diseases; Obese children; Arterial stiffness; Skin autofluorescence; | ||
| Building a clinical pharmacology framework for the safe and effective use of antifungal agents | Lempers VJC | Burger D.M., prof. dr. | Brüggemann R.J.M., PhD | Aarnoutse R.E., dr. | Radboud Universiteit (RU) | 2016 | Antifungal drugs; Clinical pharmacology; | |
| Neurovascular pharmacology of migraine: epigenetics and sex hormones | Labruijere S., PhD | Danser A.H.J., prof. dr. | Maassen van den Brink A., dr. | Erasmus Universiteit Rotterdam (EUR) | 2014 | Pharmacology; Migraine; Epigenetics; Neurovascular pharmacology; | ||
| Peripheral Projections of the Trigeminovascular System as Antimigraine Target | Labastida Ramírez A | Danser A.H.J., prof. dr. | Maassen van den Brink A., dr. | Erasmus Universiteit Rotterdam (EUR) | 2019 | Migraine; Vascular reactivity; Pharmacology; | ||
| Intranasal drug delivery in migraine | Kuy P.H.M. van der, dr. | Merkus F.W.H.M., prof. dr. | Lohman J.J.H.M., dr. | Universiteit Leiden (UL) | 2003 | Migraine; Intranasal | ||
| The association between albuminuria and long-term renal risk; how to improve the precision of drug effect estimates | Kröpelin T.F., PhD | Zeeuw D. de, prof. dr. | Lambers Heerspink H.J., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2016 | Kidney; Diabetic kidney disease; Drug efficacy; | ||
| (Pro)renin revisited: new insights from studies in mast cells | Krop M., dr. | Danser A.H.J., prof. dr. | Erasmus Universiteit Rotterdam (EUR) | 2009 | Cardiovascular disease; Pharmacology; Prorenin; | |||
| Size does matter : drug glucuronidation in children | Krekels E.H.J., PhD | Knibbe C.A.J., prof. dr. | Tibboel D., prof. dr. | Universiteit Leiden (UL) | 2012 | Paediatrics; Morphine; Population PK; System-specific covariate modelling; Model validation; Glucuronidation; Ontogeny; Pharmacokinetics; UGT2B7; Zidovudine; | ||
| Challenges in the clinical development of orphan drugs | Kreeftmeijer-Vegter A.R., PhD | Boer A. de, prof. dr. | Vries P.J. de, dr. | Universiteit Utrecht (UU) | 2015 | Orphan drugs; Clinical development; Paediatric formulation; Pharmacokinetics; Efficacy; Safety; Regulatory; | ||
| The influence of the sample matrix on LC-MS/MS method development and analytical performance | Koster R.A., PhD | Uges D.R.A., prof. dr. | Kosterink J.G.W., prof. dr. | Alffenaar J.W.C., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2015 | ||
| Towards better treatment outcomes in childhood asthma | Koster E.S., PhD | Raaijmakers J.A.M., prof. dr. | Maitland-van der Zee A.H., prof. dr. | Universiteit Utrecht (UU) | 2011 | Asthma; Children; Treatment Outcomes; Epidemiology; | ||
| Pharmacokinetic insights in individual drug response; a model-based approach to quantify individual exposure-response relationships in type 2 diabetes | Koomen J.V. | Lambers Heerspink H.J., prof. dr. | Mol P.G.M., dr. | Stevens J., Dr. | Rijksuniversiteit Groningen (RUG) | 2021 | Pharmacokinetic insights in individual drug response; a model-based approach to quantify individual exposure-response relationships in type 2 diabetes | |
| Investigations of skin inflammation with a novel dermatology toolbox for early phase clinical drug development | Kolk T. van der, dr | Burggraaf J., prof. dr. | Rissmann R, prof.dr. | Universiteit Leiden (UL) | 2021 | Skin inflammation Dermatology toolbox Early phase clinical drug development Trial at home Inflammation models Skin microbiome Atopic dermatitis | ||
| Techniques to improve neurological outcome after cardiac surgery | Kok W.F., PhD | Henning R.H., prof. dr. | Absalom A.R., prof. dr. | Scheeren T.W.L., prof. dr. | Rijksuniversiteit Groningen (RUG) | 2017 | Cardiac surgery; Clinical pharmacology; Neurological outcome; | |
| Novel approaches in clinical development of cannabinoid drugs | Klumpers L.E., PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2014 | Cannabinoids; THC; CB1 antagonists; Pharmacokinetics; Clinical pharmacology; Pharmacodynamics; Feeling high; PK-PD modelling; Resting state FMRI; Rimonabant; | ||
| Drug-induced psychomimetic symptoms as a model for psychosis | Kleinloog-Fernández González H.D., PhD | Gerven J.M.A. van, prof. dr. | Cohen A.F., prof. dr. | Universiteit Leiden (UL) | 2014 | Clinical Pharmacology Psychotic Disorders Clinical Trial Drug evaluation Biological Models | ||
| Minimally invasive methodology for pharmacological research involving children | Klein R.H., PhD | Cohen A.F., prof. dr. | Burggraaf J., prof. dr. | Sukhai R.N., dr. | Universiteit Leiden (UL) | 2013 | Paediatrics; Clinical pharmacology; ADHD; Pharmacokinetics; Growth hormone deficiency; Pharmacodynamics; Point of care technology; | |
| Harmonising relative effectiveness assessments of medicines in Europe | Kleijnen S., PhD | Boer A. de, prof. dr. | Leufkens H.G.M., prof. dr. | Goettsch W.G., dr. | Universiteit Utrecht (UU) | 2016 | Medicines; Relative effectiveness; Reimbursement; Harmonisation; Europe; Methods; Health technology assessment (HTA); | |
| Clinical pharmacology and bioanalysis of antileishmanial drugs : Towards improved treatment strategies for leishmaniasis | Kip A.E., PhD | Beijnen J.H., prof. dr. | Schellens J.H.M., prof. dr. | Dorlo T.P.C., dr. | Universiteit Utrecht (UU) | 2017 | Leishmaniasis; Clinical pharmacology; Bioanalysis; Pharmacokinetics; Pharmacodynamics; Miltefosine; Amphotericin B; Neopterin; |